FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine Post author:PacConAdmin Post published:July 15, 2025 Post category:Uncategorized Post comments:0 Comments FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine Source: FDA Press Releases Tags: aaps Read more articles Previous PostFDA Approves Gardenia (Genipin) Blue Color Additive While Encouraging Faster Phase-Out of FD&C Red No. 3 Next PostFDA to Revoke 52 Obsolete Standards of Identity for Food Products You Might Also Like Nostrum Labs Agrees to Pay Up to $50 Million Over Underpayment of Medicaid Rebates October 31, 2023 Industry Says it Needs More Time to Comply With Drug Supply Chain Security Requirements February 23, 2024 Eitan Medical Recalls Infusion Pumps for Failure to Detect Air in the Line December 1, 2023 Leave a Reply Cancel replyCommentEnter your name or username to comment Enter your email address to comment Enter your website URL (optional) Save my name, email, and website in this browser for the next time I comment.
Industry Says it Needs More Time to Comply With Drug Supply Chain Security Requirements February 23, 2024